Inhibition of mitochondrial permeability transition selectively suppresses thrombogenic platelet procoagulant activity.

Inhibiting mitochondrial permeability transition pore (mPTP) reduces procoagulant platelet activity and thrombosis without impairing hemostasis, with a 50% reduction in thrombin generation.

• Why it matters: Excessive platelet procoagulant activity contributes to thrombosis, but current methods risk impairing necessary hemostatic functions. Targeting mPTP offers a potential selective approach to prevent pathological clotting.
• What they did: Researchers tested three novel cyclophilin D-independent mPTP inhibitors—MC63, TR001, and TR002—on platelets under procoagulant conditions, assessing mitochondrial function, calcium overload, and thrombus formation through in vitro and in vivo models.
• The result: mPTP inhibitors preserved mitochondrial integrity, reduced procoagulant markers, and decreased thrombin and fibrin formation within thrombi, all without affecting normal platelet functions or bleeding times, indicating a promising antithrombotic strategy.